Table 1. United States Food and Drug Administration approval of agents for NETs within the last 10 years.
Date of FDA approval | Drug | Indication |
---|---|---|
05/06/2011 | Everolimus | Unresectable, locally advanced or metastatic, progressive pancreatic NET |
05/20/2011 | Sunitinib | Unresectable, locally advanced or metastatic, progressive pancreatic NET |
12/16/2014 | Lanreotide | Unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival |
02/26/2016 | Everolimus | Unresectable, well differentiated, locally advanced or metastatic, non-functional, progressive gastrointestinal or lung NET |
FDA, Food and Drug Administration; GEP, gastroenteropancreatic; NETs, neuroendocrine tumors.